COMP <GO>
APUS vs ADXN // RSI-14 & 200D SMA MOMENTUM
Apimeds Pharmaceuticals US Inc. (NYSE) VS. Addex Therapeutics Ltd (NASDAQ) • 15-METRIC TALLY: APUS 0
— ADXN 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ADXN
LAST: $3.21 (+4.56%) • MKT CAP: $5.0M
rsi-technicals
42.4
LAST: $2.93 (-1.01%) • MKT CAP: $5.0M
rsi-technicals
49.0
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (APUS VS. ADXN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | APUS | ADXN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -6.20% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 42.4 | 49.0 | -6.62 | ADXN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.0M | $5.0M | -$40.1K | ADXN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | APUS REV | ADXN REV | APUS GROSS % | ADXN GROSS % | APUS FCF | ADXN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | -$9.0M | — |
| FY 2024 | $0 | — | — | — | -$733.5K | — |
| FY 2023 | $0 | — | — | — | -$627.8K | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
APUS // BETA —
ADXN // BETA —